Non-Hodgkin’s lymphoma (NHL)

NHL is a cancer originating from the lymphocytes, a type of white blood cell which is part of the body’s immune system

Non-Hodgkin’s lymphoma is a cancer originating from the lymphocytes, a type of white blood cell which is part of the body’s immune system.[1] NHL can occur at any age although it is more common in adults over 50 years old.[2] Initial symptoms usually are enlarged lymph nodes, fever, and weight loss.[3]

There are many different types of NHL. These types can be divided into aggressive (fast-growing) and indolent (slow-growing) types, and they can be formed from either B lymphocytes (B cells) or in lesser extent from T lymphocytes (T cells) or Natural Killer cells (NK cells).[4]

In 2020, there were approximately 550,000 new cases of non-Hodgkin lymphoma worldwide, and an estimated 281,000 deaths were attributed to the disease during that same period.[5] The incidence remains the highest in Western countries, while regions of Africa, Western Asia, and Oceania continued to experience high mortality rate.[6]

Prognosis and treatment of NHLs depend on various factors, including the stage and type of the disease. Although there is currently no cure for NHL, advances in treatments, such as chemotherapy, radiation therapy, immunotherapy, and targeted therapy, have improved prognosis for individuals living with the disease.[7] [8]

[2] American Cancer Society. (2021). Key Statistics for Non-Hodgkin Lymphoma. Retrieved from
[3] American Cancer Society. (2021). Signs and Symptoms of Non-Hodgkin Lymphoma. Retrieved from
[4] American Cancer Society. (2021). Types of Non-Hodgkin Lymphoma. Retrieved from
[5] Chu Y, Liu Y, Fang X, Jiang Y, Ding M, Ge X, Yuan D, Lu K, Li P, Li Y, Xu H, Fan J, Zhou X, Wang X. The epidemiological patterns of non-Hodgkin lymphoma: global estimates of disease burden, risk factors, and temporal trends. Front Oncol. 2023 Jun 2;13:1059914. doi: 10.3389/fonc.2023.1059914. PMID: 37333805; PMCID: PMC10272809.
[6] International Agency for Research on Cancer. (2020). Global Cancer Observatory: Cancer Today. Retrieved from
[7] National Cancer Institute. Non-Hodgkin Lymphoma Treatment (PDQÒ)-Health Professional Version. Updated July 14, 2021. Accessed October 25, 2021. https//
[8] Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068. doi:10.1200/JCO.2013.54.8800.

Our decentralized T-cell manufacturing platform

Galapagos’ decentralized T-cell manufacturing platform consists of

  • an end-to-end xCellit® workflow management and monitoring software system,
  • a decentralized, functionally closed, automated manufacturing platform for cell therapies (using Lonza’s Cocoon®) and
  • a proprietary quality control (QC) testing and release strategy.

The combination of these three core components allows for the administration of a fresh product, a median vein-to-vein time of 7 days (i.e. the time between T-cell collection and T-cell infusion), and greater physician oversight throughout the process.

The Cocoon® Platform is a registered trademark of Lonza Group AG


Our commitment in oncology

Do you need everything in one place about our efforts in redefining the future of cancer treatments?

Pioneer with us in Oncology

This is your call for purpose!

Do you want to pioneer for patients in Oncology? Discover our vacancies!

Disease areas

More about our work in Immunology

We strive to accelerate innovation of transformational medicines that deliver more years of life and quality of life for patients and families living with cancer.


Work with us!

We combine internal and external innovation to add new capabilities, technologies and product candidates. Let’s start #PioneeringForPatients, together!

Galapagos Health

Explore our HCP Portal

Are you a healthcare professional? Are you looking for Galapagos’ medical education, product information or congress presence? Look no further!